QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=0DF0200610D5755FCAF94D458ED3A548;jsessionid=308996901916739E67926A496DDB2DE4;jsessionid=46D2C583C6DC56721E9FDECFBCDBA880;jsessionid=039BABAFF1A2DC126B368481431E7435;jsessionid=E3DF8F22E92D982D1D1A0889FD9A608D;jsessionid=89331CEB00148341365C32CF8E134197;jsessionid=36FC9019020DF9DCEB26A6875D427C37;jsessionid=31EA248C7FB6DEDF413A0B4706152B05 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=0DF0200610D5755FCAF94D458ED3A548;jsessionid=308996901916739E67926A496DDB2DE4;jsessionid=46D2C583C6DC56721E9FDECFBCDBA880;jsessionid=039BABAFF1A2DC126B368481431E7435;jsessionid=E3DF8F22E92D982D1D1A0889FD9A608D;jsessionid=89331CEB00148341365C32CF8E134197;jsessionid=36FC9019020DF9DCEB26A6875D427C37;jsessionid=31EA248C7FB6DEDF413A0B4706152B05